KMID : 1188320180120030255
|
|
Gut and Liver 2018 Volume.12 No. 3 p.255 ~ p.262
|
|
Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn¡¯s Disease Patients
|
|
Choi Jae-Young
Kang Ben Kim Min-Ji Sohn In-Suk Lee Hae-Jeong Choe Yon-Ho
|
|
Abstract
|
|
|
Background/Aims: Information regarding the efficacy of early infliximab treatment in pediatric patients with Crohn¡¯s disease (CD) is limited. We aimed to evaluate the impact of early combined immunosuppression on linear growth in pediatric patients with CD by performing step-up comparisons.
Methods: This retrospective study included pediatric patients with moderate-to-severe CD, who received a combination therapy with infliximab and azathioprine for at least 3 years and sustained corticosteroid-free remission without loss of response. The z-scores of the growth indicators obtained at the time of diagnosis and annually for 3 years thereafter were compared between the two groups.
Results: The early combined immunosuppression group displayed significantly increased linear growth 3 years after diagnosis (p=0.026). A significant difference was also observed in the linear growth 3 years after diagnosis between subgroups of Tanner stages 1?2 (p=0.016).
Conclusions: The early introduction of biologics should be considered to improve linear growth in pediatric patients with CD.
|
|
KEYWORD
|
|
Infliximab, Growth, Height, Tanner stage
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|